source
- ADARx aims for $318 million IPO as TRexBio and Retension also fileADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
- TRex Bio and Retension Pharma announce plans for IPOs, outlining biotech pipeline fundingBiotech companies Retension Pharmaceuticals and TRex Bio have filed with the SEC indicating they intend to go public this year, adding to the current wave of biotech IPOs. TRex Bio said it will us…